JP2018500274A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500274A5
JP2018500274A5 JP2017516948A JP2017516948A JP2018500274A5 JP 2018500274 A5 JP2018500274 A5 JP 2018500274A5 JP 2017516948 A JP2017516948 A JP 2017516948A JP 2017516948 A JP2017516948 A JP 2017516948A JP 2018500274 A5 JP2018500274 A5 JP 2018500274A5
Authority
JP
Japan
Prior art keywords
group
core sequence
seq
ala
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500274A (ja
JP6851965B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/052467 external-priority patent/WO2016049580A2/en
Publication of JP2018500274A publication Critical patent/JP2018500274A/ja
Publication of JP2018500274A5 publication Critical patent/JP2018500274A5/ja
Application granted granted Critical
Publication of JP6851965B2 publication Critical patent/JP6851965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516948A 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Active JP6851965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036502A Division JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2018500274A JP2018500274A (ja) 2018-01-11
JP2018500274A5 true JP2018500274A5 (https=) 2019-05-09
JP6851965B2 JP6851965B2 (ja) 2021-03-31

Family

ID=55582262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Country Status (7)

Country Link
US (5) US10030048B2 (https=)
EP (1) EP3197474B1 (https=)
JP (3) JP6851965B2 (https=)
CN (2) CN114432423A (https=)
AU (2) AU2015320341B2 (https=)
CA (1) CA2999711A1 (https=)
WO (1) WO2016049580A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432423A (zh) 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CA3191058A1 (en) * 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3039802B2 (ja) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
WO1991002537A1 (en) 1989-08-14 1991-03-07 The Regents Of The University Of California Synthetic peptides that enhance cell binding
AU1404395A (en) * 1993-12-13 1995-07-03 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3987120B2 (ja) * 1996-09-05 2007-10-03 リサーチ ディベロップメント ファンデーション カフェイン酸フェネチル・エステル（ＣＡＰＥ）、ＣＡＰＥの誘導体、カプサイシン（８―メチル―Ｎ―バニリル―６―ノネンアミド）及び樹脂分泌毒素による核転写ファクターＮＦ―κＢの抑制
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
DK1678209T3 (da) * 2003-10-07 2011-06-27 Yeda Res & Dev Antistoffer mod nik, deres frembringelse samt anvendelse
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
JP5702371B2 (ja) * 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
WO2011087768A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
CN114432423A (zh) 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
CA3191058A1 (en) 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Similar Documents

Publication Publication Date Title
ES2581381T3 (es) Composiciones y métodos de inhibición de la gripe
Piccoli et al. Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch
ES2212121T3 (es) Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12).
DK1927597T3 (en) ANTIBACTERIAL PEPTIDES
JP2011173914A5 (https=)
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
JP2018500274A5 (https=)
JP2013518057A5 (https=)
JP2022546130A (ja) 合成抗菌ペプチド
JPWO2019156137A5 (https=)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
DK2956155T3 (en) Short bioactive peptides to promote wound healing
EP3322429B1 (en) Growth promoting peptides and uses thereof
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
RU2008146731A (ru) Модуляция липидных рафтов
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
JP2016521746A5 (https=)
CA2655448A1 (en) Cyclic antimicrobial peptides
JP2021091728A5 (https=)
JP2023010979A5 (https=)
JP6548126B2 (ja) Ｉｉｉ型コラーゲン産生促進剤
US20140194594A1 (en) Synthetic peptides and peptide mimetics
JP2017513856A5 (https=)
JPWO2021070696A5 (https=)
WO2009005798A8 (en) Antifungal formulation and method of preparation